CytoReason
Machine Learning for Data-driven Target Discovery and Drug Development
StartupCytoReason is a --based startup in the Health Tech & Life Sciences sector, established in 2016. Machine Learning for Data-driven Target Discovery and Drug Development. The company has raised a total of $132M across 6 funding rounds, currently at the C stage. CytoReason was founded by Shai Shen-Orr, David Harel, Elina Starosvetsky, Ksenya Kveler, Yuval Kalugny. Key investors include Nvidia, Pfizer, OurCrowd, among 6 total investors. The company has 51-200 employees. Core technologies: Biologicals, Cells, Artificial Intelligence, Machine Learning.
With $132M in total funding, CytoReason is a C-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Released.
- StageC
- ProductReleased
- ModelB2B
- Employees51-200
- HQ -
- Last Round$80M
- Nvidia
- Pfizer
- OurCrowd
6 investors total
Shai Shen-OrrCo-founder & CSODavid HarelCo-founder & President
Elina StarosvetskyCo-founder & VP Experimental Biology
Ksenya KvelerCo-founder (No longer with the company)
Yuval KalugnyCo-founder (No longer with the company)
23 articles covered by sources including en.globes.co.il,
pharmatimes.com,
www.timesofisrael.com,
www.calcalistech.com,
www.prnewswire.com.
What does CytoReason do?
CytoReason is a technology company developing a computational model of the human body that simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials more focused and accurate. With CytoReason's proprietary database and AI-led platform, pharmaceutical and biotechnology companies can make data-driven decisions quickly and cost effectively. To date, five of the world’s top ten pharma companies use CytoReason’s technology to identify new opportunities, shorten trial phases, reduce development costs, and increase the likelihood of drug approval.
How much funding has CytoReason raised?
CytoReason has raised $132M in total funding across 6 rounds. The company is currently at the C stage. Key investors include Nvidia, Pfizer, OurCrowd.
Who founded CytoReason?
CytoReason was founded in 2016 by Shai Shen-Orr (Co-founder & CSO), David Harel (Co-founder & President), Elina Starosvetsky (Co-founder & VP Experimental Biology), Ksenya Kveler (Co-founder (No longer with the company)), Yuval Kalugny (Co-founder (No longer with the company)).
What sector is CytoReason in?
CytoReason operates in Health Tech & Life Sciences, Digital Healthcare, Medical Decision Support, with core technologies in Biologicals, Cells, Artificial Intelligence, Machine Learning. Target customers: Healthcare & Life Sciences, Life Sciences, Pharmaceuticals, Healthcare, Providers, Laboratories.
Where is CytoReason located?
CytoReason is based in Derech Menachem Begin 132, Tel Aviv-Yafo, Israel.